Introduction
Oncogenic gene fusions involving neuregulin 1 (NRG1) have emerged as recurrent aberrations in lung adenocarcinomas [1] [2] [3] [4] [5] and have been proposed to represent a druggable signaling axis [1, [6] [7] [8] , which has recently been demonstrated in the clinical setting [9] , but until now the demonstration of the significance of these gene fusions has been limited to lung cancers. Here, we describe two patients with NRG1 fusion-positive cancer as detected by whole-genome and transcriptome sequencing. The first patient had a primary lung adenocarcinoma, while the second had a primary intrahepatic cholangiocarcinoma, a disease type in which NRG1 fusions have not been described previously. Both were treated with the HER-family kinase inhibitor afatinib and both displayed significant and durable responses. These observations represent the first reported demonstration of a pan-HER tyrosine kinase inhibitor response in NRG1 fusion-positive cancers outside of lung cancer in a clinical setting, which has significant implications for the detection and treatment of NRG1 fusion-positive cancers.
Methods
Patients were enrolled in our ongoing study at the BC Cancer Agency in Vancouver, British Columbia, entitled 'Personalized Onco-Genomics (POG)', which enrolls patients with metastatic cancers of all subtypes. Individual's cancers undergo whole-genome DNA and RNA sequencing and in-depth bioinformatic analyses in order to identify somatic variants and gene expression changes that may be targetable cancer 'drivers'. Aberrant pathways are matched to drug databases and these data are reported to the clinician for each individual patient. The study was approved by the University of British Columbia Research Ethics Committee (REB# H12-00137) and written informed consent was obtained from each patient before genomic profiling. Patient identity was anonymized within the research team and an identification code was assigned to the case for communicating clinically relevant information to physicians. The patients consented to potential publication of findings. Raw sequence data and downstream analytics were maintained within a secure computing environment.
Whole-genome and transcriptome sequencing
Fresh tumor biopsy and a blood sample were collected for comprehensive DNA and RNA sequencing [10] . The mean redundant depth of coverage for the constitutional and tumor samples was 40Â and 80Â, respectively and transcriptomes of approximately 200M reads were generated (for details see supplementary Table S1 , available at Annals of Oncology online). Somatic point mutations, small insertions or deletions (indels), and copynumber alterations, detected in the tumor DNA but not in the germline, were identified. De novo assembly of genomic and transcriptomic data was carried out to detect rearrangements. Publicly available transcriptome sequencing data from the illumina bodymap and The Cancer Genome Atlas (TCGA) were used to explore the expression profile of human genes and transcripts. A within-sample expression rank was also calculated to further infer significance to outlier gene expression levels. For details, see supplementary Methods, available at Annals of Oncology online.
Sequencing data availability
Genomic and transcriptomic datasets have been deposited at the European Genome-phenome Archive [EGA, http://www.ebi.ac.uk/ega/ (26 September 2017, date last accessed)] under accession numbers EGAD00001002564 (patient 1), EGAD00001002623 (patient 2).
NRG1 FISH protocol
Fluorescent in situ hybridization was carried out using the Dako Histology FISH Accessory Kit as per manufacturer's protocol. Slides were scored manually using an oil immersion Â63 objective and z-stack images were captured using Metasystems software (MetaSystems Group Inc., Belmont, MA). For details, see supplementary Methods, available at Annals of Oncology online.
Results
Patient 1 was a 43-year-old woman, lifelong never-smoker, who presented with moderately differentiated adenocarcinoma of the lung with multiple intrathoracic metastases in October 2013. Standard tests for the presence of an EGFR mutation and ALK fusion were negative. She received four cycles of standard carboplatin-pemetrexed chemotherapy with minimal response. Upon progression she was consented and enrolled in the POG clinical trial. Somatic genomic abnormalities were identified and analyzed for actionable and informative anomalies, as well as candidate druggable targets. Whole-genome sequencing identified 21 somatic mutations [Single Nucleotide Variants (SNVs) and Indels] predicted to impact protein-coding genes in the metastatic tumor of patient 1 (see supplementary Table S2 , available at Annals of Oncology online), none of which had been described previously in the literature and were not deemed to be clinically actionable. Genome-wide copy-number analysis revealed no copy number gains of known clinical or therapeutic relevance. Our analysis identified two potentially actionable observations. The first was detected as a consequence of mRNA overexpression of the NOTCH1 gene (see supplementary Figure S1 , available at Annals of Oncology online). Activation of NOTCH signaling pathway has been described as an oncogenic and potentially actionable event in lung cancer [11] . The patient was initially enrolled on a phase I clinical trial of a NOTCH inhibitor but withdrew from the study after 3 months due to significant toxicity. Her best response to this agent was stable disease. The second observation was of a gene fusion between exon 2 of SDC4 and exon 4 NRG1 ( Figure 1A and D), evidence of which was detected by de novo assembly in both the genome and transcriptome data (see supplementary Table S3 , available at Annals of Oncology online). Fusion of SDC4 to NRG1 had been described previously in a patient with adenocarcinoma of the lung and the proposed mechanism is that the SDC4-NRG1 fusion produces a secretory NRG1 protein due to the signal peptide contributed by SDC4 protein [2] . No apparent over-expression of NRG1 associated with the gene fusion was detected when compared with expression data from a normal lung sample or a cohort of lung adenocarcinomas from TCGA (supplementary Figure S2 , available at Annals of Oncology online). Having failed to respond to the phase I trial a more experimental approach was taken; at the time the patient was initiated on afatinib therapy (at 30 mg orally per day) based on preclinical reports of the potential efficacy of this treatment in NRG1 fusion-positive lung cancer models [8, 12] . Treatment with afatinib resulted in a rapid and durable response with minimal drug-associated toxicities (Figure 2A and B). Her response was maintained for 12 months at which point the cancer progressed in the lung, liver, and brain. Afatinib treatment was stopped and a second biopsy for POG analysis was taken from a growing liver lesion. This repeat analysis detected the maintained presence of the fusion, and although the cancer had acquired new mutations (see supplementary Table S2 , available at Annals of Oncology online), none of these could be identified as a clear mechanism to explain her acquired resistance to afatinib and no additional mutations in NRG1 were observed.
Patient 2 was a 38-year-old woman who presented with abdominal pain and was subsequently diagnosed with locally advanced intrahepatic cholangiocarcinoma in September of 2014. She received seven cycles of chemotherapy with gemcitabine and cisplatin and achieved a minor response, after which she underwent surgery. At the time of surgery, her cancer was found to be more extensive than anticipated with multiple tumor nodules studding the liver. Plans for an aggressive resection were abandoned and a wedge biopsy of the involved liver was taken for genomic testing. Whole-genome analysis of this sample identified 51 somatic mutations (SNVs and Indels) predicted to impact protein-coding genes (see supplementary Table S4 , available at Annals of Oncology online) in the metastatic tumor, none of which were described previously in the literature and were not considered actionable. Genome-wide copy-number analysis revealed copy number changes characteristic of cholangiocarcinomas [13, 14] (supplementary Figure S3 , available at Annals of Oncology online), none of which were associated with a specific therapeutic action. Analysis of the de novo assembly of the genome and transcriptome sequence data revealed a novel fusion of exon 2 of the ATP1B1 gene to exon 2 of NRG1 (Figure 1A and  supplementary Table S3 , available at Annals of Oncology online). The resulting ATP1B1-NRG1 fusion had not previously been reported in the literature but was predicted to be an in-frame fusion preserving the EGF-like domain, which has been shown to be required for NRG1 function [3, 5] (Figure 1D ). ATP1B1 encodes for the beta subunit of the Naþ/Kþ ATPase, an integral membrane protein and encodes an N-terminal transmembrane domain, which is retained in the predicted fusion product ( Figure 1D ). The presence of the fusion was confirmed by breakapart FISH ( Figure 1B) , and correlation of NRG1 expression to publically available expression data (Illumina Bodymap; TCGA) revealed particularly strong expression of the gene at 23-fold higher than in normal liver tissue and in the 100th percentile for expression when compared with a dataset of 37 intrahepatic cholangiocarcinomas from TCGA ( Figure 1C ). Together, these data supported that this novel fusion involving the NRG1 gene was a functional oncogenic driver and afatinib the predicted targeted agent of choice in this tumor. In the intervening time between biopsy for POG and return of the full analysis the patient had chosen to pursue an alternative form of treatment and at that time opted to remain committed to the course of alternative therapies. The identities of which treatments she received during that time are unknown although these agents did cause cyclic neutropenia. After 7 months, there was clear evidence of disease progression and functional decline and the patient consented to off-label treatment with afatinib. Once treatment was initiated her response was rapid and dramatic; her ECOG PS showed rapid improvement, her CA 19.9 fell from 1700 to 120 kU/l in 25 days and her imaging improved significantly at 14 weeks ( Figure 2C and D) . This patient initiated afatinib at 40 mg orally per day but required a dose reduction to 30 mg daily due to skin rash and diarrhea; both expected and manageable toxicities associated with HER2-family kinase inhibitors [15] . She maintained a response for 8 months and then developed new sites of metastases. A repeat biopsy of one of these sites was carried out analysis detected of which confirmed the maintained presence of the fusion, and although the cancer had acquired new mutations (see supplementary Table S4 , available at Annals of Oncology online), none of these impacted NRG1 or could be identified as a clear mechanism to explain the acquired resistance to afatinib.
Discussion
Patient 1 presented with SDC4-NRG1 fusion-positive advanced invasive lung cancer that displayed a rapid and durable partial response to afatinib despite an extensive tumor burden. NRG1 fusions are well established as oncogenic drivers that have been associated with lung cancers previously, including those of a mucinous subtype [2] [3] [4] [5] [6] [16] [17] [18] [19] . The response observed as a consequence of afatinib therapy suggests a primary role for the activity of the HER-family proteins driven by the NRG1 fusion in the growth and maintenance of the patient's tumor. The lack of other gross genomic events, such as copy number changes or potentially oncogenic gene mutations, revealed by whole-genome analysis is consistent with this hypothesis.
Targeting this tumor with afatinib was an approach with a clear molecular rationale. NRG1, a member of the neuregulin family, is a known ligand for the HER3 (ERBB3) receptor that, when activated by NRG1 binding, forms a heterodimer with other HERfamily receptors and regulates downstream signaling pathways, leading to multiple effects including growth, proliferation, decreased apoptosis, cellular migration and angiogenesis [6, 20] . Abrogating NRG1 expression in lung cancer models affects cell proliferation [2] and enhances the magnitude and duration of the response to standard first line chemotherapy agents [12] . Furthermore, tumor cells expressing NRG1 have been shown to be responsive to EGFR, HER2, and HER3 inhibitors in human tumor models in the preclinical setting [8, 21] , including lapatinib and afatinib [8] , with afatinib reported as being the most effective [22] . The validity of this approach was evidenced by the patient's positive response to treatment, which has recently been observed in two additional patents with NRG1-fusion positive lung cancers [9] .
Patient 2 presented with intrahepatic cholangiocarcinoma harboring a novel NRG1 fusion event. NRG1 rearrangements are not limited to lung cancer, having been described in other cancer types previously [20, 23] . However, to our knowledge, NRG1 fusions have not been reported in cholangiocarcinoma. Of note, gene fusions involving FGFR2 are a recurrent occurrence in this disease type and are emerging as oncogenic drivers that are potentially characteristic of a subtype of the disease [24, 25] . This suggests that the underlying biological mechanisms leading to gene rearrangement are active in this cancer type and further indicates that broader investigation of the frequency of NRG1 fusions in both this and other cancer types is warranted. Given the novel gene partner of the NRG1 fusion in this patient, assessing the likelihood that the fusion was a driver of the disease was an important consideration before embarking upon off-label therapy. The prediction that the novel ATP1B1-NRG1 fusion retained an intact EGF domain was significant given that this domain is required for NRG-dependent stimulation of HERreceptor dimerization and that an NRG1 gene fusion lacking the EGF-like domain was reported to be unable to promote oncogenic properties in a preclinical model [5] . Furthermore, since ATP1B1 encodes an N-terminal transmembrane domain, which was retained in the predicted fusion product, the novel fusion protein may be targeted and bound to the membrane exposing the active domains of NRG1 externally to the cells, a mechanism that has been proposed for other NRG1 fusions [5] . Additionally, outlier overexpression of NRG1 mRNA was observed ( Figure  2C ). Upregulation of NRG1 is a well-documented mechanism of resistance to chemotherapy in melanomas [26, 27] and HER2-positive breast cancer models [28, 29] , and is a mechanism of resistance to ALK inhibitors in ALK-positive lung cancer [22, 30] . Together, these observations and the lack of other known oncogenic drivers in this tumor supported the hypothesis that the NRG1 fusion was a driver of this disease. Finally, at the time of when this case was being evaluated the striking response to afatinib in patient 1 had already been observed. Overall, the data provided a strong rationale for a similar targeted therapy approach for this novel NRG1 fusion despite a lack of previous description in the literature, and the rapid and pronounced response of patient 2 confirmed this reasoning.
This report of NRG1 fusions and corresponding response to afatinib has several significant implications for translation of these findings to clinical care. The clear molecular rationale and preclinical evidence for the effectiveness of the HER inhibitor afatinib in NRG1 fusion-positive cancers is validated by the rapid and pronounced response in these two patients, despite the differences in cancer type and structure of the NRG1 fusion. Clinical tests with the ability to detect rare but actionable genomic events including NRG1 fusions are being pursued [7] . What we and others have established that these fusions are highly variable as the number of documented fusion partners continues to grow [3, 5, 9] . Relevant diagnostic tests will therefore need to account for this variability. Furthermore, our finding of an NRG1 fusion and corresponding therapeutic response in a cancer type for which this fusion has not been described previously indicates that expanding screening efforts across cancer types has the potential to identify additional patients with potentially actionable NRG1 fusion-positive cancers. A basket trial to further explore this finding in a larger group of patients is needed.
Finally, it should be noted that as a primary ligand of HER3 [31] , it is possible that targeting NRG1 downstream via direct inhibition of HER3 might result in a more specific and longer response compared with a broad HER-family inhibitor such as Afatinib. To date, no HER3-targeted therapy has been approved for cancer treatment though monoclonal antibodies are reportedly under clinical evaluation [32, 33] . Further exploration of this approach is warranted.
